​

Harmony Biosciences (HRMY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HRMY Stock Forecast

Harmony Biosciences (HRMY) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $41.75, with a high of $55.00 and a low of $33.00. This represents a 40.86% increase from the last price of $29.64.

$25 $31 $37 $43 $49 $55 High: $55 Avg: $41.75 Low: $33 Last Closed Price: $29.64

HRMY Stock Rating

Harmony Biosciences stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (83.33%), 0 Hold (0.00%), 2 Sell (16.67%), and 0 Strong Sell (0.00%).

Buy
Total 12 2 0 10 0 Strong Sell Sell Hold Buy Strong Buy

HRMY Price Target Upside V Benchmarks

TypeNameUpside
StockHarmony Biosciences40.86%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts236
Avg Price Target$39.50$44.67$40.50
Last Closing Price$29.64$29.64$29.64
Upside/Downside33.27%50.71%36.64%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25361-111
Sep, 25361-111
Aug, 25361-111
Jul, 2535--19
Jun, 2535--19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 29, 2025Mizuho Securities$36.00$29.6421.46%21.46%
Oct 15, 2025UBS$43.00$26.8560.15%45.07%
Sep 25, 2025H.C. Wainwright$55.00$27.04103.40%85.56%
Jul 10, 2025Corinne JohnsonGoldman Sachs$33.00$34.33-3.87%11.34%
Apr 28, 2025UBS$48.00$29.3663.49%61.94%
Oct 30, 2024Corinne JenkinsGoldman Sachs$28.00$41.49-32.51%-5.53%
Oct 10, 2024Graig SuvannavejhMizuho Securities$52.00$33.6054.76%75.44%
Sep 10, 2024Ashwani VermaUBS$56.00$36.8951.80%88.93%
Aug 08, 2024Graig SuvannavejhMizuho Securities$42.00$33.5525.19%41.70%
Jun 24, 2024Francois BriseboisOppenheimer$56.00$30.3984.27%88.93%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 10, 2025Deutsche BankBuyBuyhold
Oct 30, 2024Cantor FitzgeraldOverweightOverweighthold
Oct 30, 2024OppenheimerOutperformOutperformhold
Oct 30, 2024Goldman SachsSellSellhold
Oct 29, 2024UBSBuyBuyhold
Oct 02, 2024UBSBuyBuyhold
Sep 12, 2024NeedhamBuyBuyhold
Sep 10, 2024UBSBuyBuyhold
Sep 09, 2024UBSBuyinitialise
Aug 06, 2024NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-1 $3 $7 $11 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.91$0.60$3.07$2.17$2.56----
Avg Forecast$-0.59$0.64$2.79$2.42$2.35$3.34$4.68$6.61$11.05
High Forecast$-0.56$0.66$2.92$2.46$2.54$3.99$6.02$10.42$11.50
Low Forecast$-0.60$0.62$2.63$2.38$2.07$2.01$3.15$4.68$10.66
Surprise %54.24%-6.25%10.04%-10.33%8.94%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$159.74M$305.44M$437.86M$582.02M$714.73M----
Avg Forecast$155.21M$303.77M$436.79M$582.76M$713.65M$852.00M$1.05B$1.31B$1.83B
High Forecast$159.11M$311.41M$452.88M$583.40M$713.68M$876.86M$1.05B$1.35B$1.89B
Low Forecast$150.68M$294.91M$418.27M$582.11M$713.61M$827.13M$1.05B$1.27B$1.78B
Surprise %2.92%0.55%0.24%-0.13%0.15%----

Net Income Forecast

$-100M $60M $220M $380M $540M $700M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-51.86M$34.60M$181.47M$128.85M$145.49M----
Avg Forecast$-35.32M$121.44M$58.46M$128.85M$139.23M$206.35M$281.05M$390.23M$667.32M
High Forecast$-33.98M$149.49M$74.29M$163.31M$153.53M$240.96M$363.44M$629.08M$694.25M
Low Forecast$-36.47M$93.40M$42.64M$94.40M$124.93M$121.42M$190.17M$282.54M$643.53M
Surprise %46.83%-71.51%210.39%-4.50%----

HRMY Forecast FAQ

Is Harmony Biosciences stock a buy?

Harmony Biosciences stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 0 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Harmony Biosciences is a favorable investment for most analysts.

What is Harmony Biosciences's price target?

Harmony Biosciences's price target, set by 12 Wall Street analysts, averages $41.75 over the next 12 months. The price target range spans from $33 at the low end to $55 at the high end, suggesting a potential 40.86% change from the previous closing price of $29.64.

How does Harmony Biosciences stock forecast compare to its benchmarks?

Harmony Biosciences's stock forecast shows a 40.86% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Harmony Biosciences over the past three months?

  • October 2025: 27.27% Strong Buy, 54.55% Buy, 9.09% Hold, 0% Sell, 9.09% Strong Sell.
  • September 2025: 27.27% Strong Buy, 54.55% Buy, 9.09% Hold, 0% Sell, 9.09% Strong Sell.
  • August 2025: 27.27% Strong Buy, 54.55% Buy, 9.09% Hold, 0% Sell, 9.09% Strong Sell.

What is Harmony Biosciences’s EPS forecast?

Harmony Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $3.34, marking a 30.47% increase from the reported $2.56 in 2024. Estimates for the following years are $4.68 in 2026, $6.61 in 2027, and $11.05 in 2028.

What is Harmony Biosciences’s revenue forecast?

Harmony Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $852M, reflecting a 19.20% increase from the reported $714.73M in 2024. The forecast for 2026 is $1.05B, followed by $1.31B for 2027, and $1.83B for 2028.

What is Harmony Biosciences’s net income forecast?

Harmony Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $206.35M, representing an 41.83% increase from the reported $145.49M in 2024. Projections indicate $281.05M in 2026, $390.22M in 2027, and $667.32M in 2028.